FOXO Technologies ( (FOXO) ) just unveiled an announcement.
On April 28, 2025, FOXO Technologies Inc. completed a 1 for 10 reverse stock split, effectively reducing its outstanding common stock from approximately 38.7 million shares to about 3.87 million shares. This strategic move, approved by the company’s directors and shareholders, aims to consolidate shares and adjust stock options and warrants, potentially impacting the company’s market positioning and shareholder value.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates three subsidiaries, including Rennova Community Health, Inc., which manages a critical access hospital in East Tennessee, Myrtle Recovery Centers, Inc., a behavioral health facility offering detox and treatment services, and Foxo Labs, Inc., a biotechnology company focused on enhancing human health and life span through innovative technology.
YTD Price Performance: -71.03%
Average Trading Volume: 5,735,741
Technical Sentiment Signal: Buy
Current Market Cap: $3.01M
Find detailed analytics on FOXO stock on TipRanks’ Stock Analysis page.